Regulatory Affairs and Pharmacovigilance in Georgia: A Practical Guide for Pharma Companies

Introduction

Georgia offers pharmaceutical companies an increasingly relevant market in the Caucasus, but market entry requires a clear understanding of local regulatory requirements. Pharmaceutical products are subject to national registration and regulatory oversight, with the Regulation Agency for Medical and Pharmaceutical Activities playing an important role in pharmaceutical regulation. U.S. trade guidance also identifies the agency as the primary regulatory body for pharmaceuticals and notes that pharmaceutical products generally need registration before being sold in Georgia.

For international manufacturers and marketing authorization holders, the challenge is not limited to obtaining an initial approval. Regulatory planning must also account for documentation, product registration, manufacturing and import requirements, pharmacovigilance, and continuing compliance.

A lifecycle-based approach can help companies identify regulatory obligations early and reduce avoidable gaps between global procedures and Georgian requirements.

Understanding Pharmaceutical Regulation in Georgia

Georgia's pharmaceutical framework is governed by national legislation, including the Law of Georgia on Medicines and Pharmaceutical Activities.

The national regulatory framework covers activities such as pharmaceutical product registration, clinical trials, pharmaceutical manufacturing, and certain import and export activities. Georgian legislation also identifies the Regulation Agency for Medical and Pharmaceutical Activities as an authority involved in pharmaceutical oversight.

For companies entering the market, regulatory planning should begin by determining:

• Product classification
• Applicable registration requirements
• Manufacturer and applicant responsibilities
• Required technical and administrative documentation
• Importation requirements
• Local regulatory responsibilities
• Post-registration obligations

The exact pathway depends on the product and its regulatory status. Consequently, Regulatory Affairs Services in Georgia can be relevant when organizations need to translate global regulatory plans into country-specific requirements.

---

Building an Effective Regulatory Strategy

A regulatory strategy should be established before dossier preparation begins.

Rather than treating registration as a documentation exercise, regulatory teams should map the entire pathway from product assessment to authorization and post-market compliance.

Key strategic considerations

A practical assessment should address:

• Intended indication and patient population
• Product classification
• Manufacturing and quality information
• Clinical and safety evidence
• Existing approvals in other jurisdictions
• Required certificates and supporting documents
• Local applicant or representative considerations
• Regulatory submission requirements
• Post-approval obligations

Georgia has also historically provided mechanisms for expedited or simplified consideration of certain products already approved by stringent foreign regulatory authorities. U.S. trade guidance notes a fast-track registration mechanism for pharmaceuticals approved by the FDA and certain other competent authorities.

Because eligibility and requirements can change, companies should verify the applicable pathway against current Georgian legislation and regulatory guidance rather than relying solely on previous submissions.

This is where Regulatory Affairs Services can support broader planning across submission preparation, regulatory documentation and lifecycle activities.

---

Pharmacovigilance and Patient Safety

Obtaining authorization is only one stage of pharmaceutical compliance.

Pharmacovigilance is essential for identifying, evaluating and managing potential risks associated with medicinal products after they enter the market.

A robust safety framework should enable companies to manage:

• Adverse event information
• Safety signals
• Individual case safety reports
• Medical literature monitoring
• Benefit-risk evaluation
• Safety communications
• Regulatory reporting
• Risk-minimization activities
• Safety-related product changes

For companies operating internationally, local pharmacovigilance processes should be aligned with the organization's global safety system while accounting for applicable Georgian requirements.

A practical Pharmacovigilance Services in Georgia framework should therefore define responsibilities, reporting workflows, documentation controls and escalation procedures.

Expert insight

The most effective pharmacovigilance systems are not designed only around reporting deadlines. They connect case processing, signal detection, regulatory affairs, medical assessment and quality systems so that safety information can trigger the appropriate regulatory action.

---

Regulatory Certification and Compliance

Regulatory certification can become an important component of pharmaceutical market access and ongoing compliance.

Depending on the product and activity, companies may encounter requirements involving manufacturing, importation, clinical research or other regulated pharmaceutical activities.

Georgian legislation contains provisions governing permissions for activities such as pharmaceutical manufacturing and clinical trials.

Companies should therefore establish a document-control system that tracks:

• Certificates and permissions
• Expiry dates
• Manufacturer information
• Product information
• Supporting technical documents
• Regulatory correspondence
• Changes requiring notification or approval

A centralized approach reduces the risk of submitting outdated or inconsistent information.

Where formal certification or regulatory documentation is required, Regulatory Certification Services can be considered as part of a structured compliance strategy.

---

Practical Checklist for Pharmaceutical Companies

Before entering or maintaining a pharmaceutical product in Georgia, regulatory teams should ask:

1. Is the product correctly classified under Georgian requirements?
2. What registration pathway applies to the product?
3. Are the manufacturer and applicant details consistent across documents?
4. Are required quality, safety and efficacy documents complete?
5. Are certificates and supporting documents current?
6. Are import and distribution responsibilities clearly defined?
7. Is the pharmacovigilance system capable of handling Georgian requirements?
8. Are safety-related regulatory responsibilities clearly assigned?
9. Are regulatory changes actively monitored?
10. Is there a lifecycle plan for maintaining compliance after registration?

This checklist can help organizations identify potential regulatory risks before they affect market access or ongoing compliance.

---

Conclusion

Pharmaceutical regulation in Georgia requires companies to look beyond initial product registration. Effective market access depends on coordinated management of regulatory strategy, documentation, certification, pharmacovigilance and post-market obligations.

The national regulatory framework places pharmaceutical activities under formal regulatory oversight, while companies remain responsible for maintaining accurate documentation and appropriate safety and compliance systems.

For international organizations, the strongest approach is to integrate Georgian requirements into the wider regulatory affairs lifecycle. Early pathway assessment, disciplined document management, continuous regulatory intelligence and effective pharmacovigilance can help create a more sustainable compliance model.

---

Why Choose DDReg as you Consulting Partner

For organizations evaluating Georgian or broader international regulatory requirements, Life Science Consulting Services (https://www.ddregpharma.com/) can provide a starting point for exploring regulatory planning and market-access considerations.

Teams monitoring regulatory developments can also explore Regulatory Intelligence Tools (https://www.ddregpharma.com/products/vitalic-regintel) to support structured awareness of changing requirements, while Regulatory Affairs Lifecycle (https://www.ddregpharma.com/products/vitalic-lc) provides a useful framework for managing regulatory activities across development, authorization and post-market stages.